This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Trevena brings in $35mm through its Series B round
14 Jul 2010
Two-year-old Trevena Inc. (developing GPCR-biased ligand therapeutics for cancer and cardiovascular and neurology conditions) has raised $35mm through its Series B venture round. Current shareholders Polaris Venture Partners and New Enterprise Associates led and were joined by all of Trevena's other existing backers--Alta Partners, Healthcare Ventures, and Yasuda Enterprise Development Co. Trevena will use the money to finish a Phase II trial of TRV120027 for acute heart failure and move other GPCR-biased ligands for pain and inflammation through discovery into the clinic.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?